Vernalis Research

Vernalis Research is a long-established, private drug discovery services and collaboration company based in Cambridge, UK. It leverages a 25+ year track record and a comprehensive technology platform centered on fragment-based drug discovery (FBDD), DNA-encoded libraries (DEL), and structural biology to enable partners' programs against challenging targets. The company operates a fee-for-service and collaborative partnership model, working with a range of pharmaceutical and biotech organizations, and does not appear to have its own proprietary clinical-stage pipeline.

Integrated structure-based drug discovery platform combining fragment-based screening, DNA-encoded library (DEL) technology, biophysical validation (SPR, ITC, NMR, X-ray), medicinal chemistry, and computational biology.

Vernalis competes in the fragmented drug discovery services market against large global CROs (e.g., Evotec, WuXi AppTec) and specialized fragment/structure-based boutiques (e.g., Astex Pharmaceuticals' collaboration model, smaller private firms). Its differentiation lies in its 25-year heritage in FBDD, deep integration of structural biology, and reputation for tackling very challenging targets.